These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 31049885)

  • 1. Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy.
    Wheless JW; Dlugos D; Miller I; Oh DA; Parikh N; Phillips S; Renfroe JB; Roberts CM; Saeed I; Sparagana SP; Yu J; Cilio MR;
    CNS Drugs; 2019 Jun; 33(6):593-604. PubMed ID: 31049885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
    Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
    Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study.
    Mitelpunkt A; Kramer U; Hausman Kedem M; Zilbershot Fink E; Orbach R; Chernuha V; Fattal-Valevski A; Deutsch L; Heffetz D; Sacks H
    Epilepsy Behav; 2019 Sep; 98(Pt A):233-237. PubMed ID: 31394352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy.
    Ben-Menachem E; Gunning B; Arenas Cabrera CM; VanLandingham K; Crockett J; Critchley D; Wray L; Tayo B; Morrison G; Toledo M
    CNS Drugs; 2020 Jun; 34(6):661-672. PubMed ID: 32350749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.
    Sands TT; Rahdari S; Oldham MS; Caminha Nunes E; Tilton N; Cilio MR
    CNS Drugs; 2019 Jan; 33(1):47-60. PubMed ID: 30460546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study.
    Reithmeier D; Tang-Wai R; Seifert B; Lyon AW; Alcorn J; Acton B; Corley S; Prosser-Loose E; Mousseau DD; Lim HJ; Tellez-Zenteno J; Huh L; Leung E; Carmant L; Huntsman RJ
    BMC Pediatr; 2018 Jul; 18(1):221. PubMed ID: 29981580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate Potential Drug-Drug Interactions Between Cannabidiol and Clobazam.
    VanLandingham KE; Crockett J; Taylor L; Morrison G
    J Clin Pharmacol; 2020 Oct; 60(10):1304-1313. PubMed ID: 32652616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
    Devinsky O; Patel AD; Cross JH; Villanueva V; Wirrell EC; Privitera M; Greenwood SM; Roberts C; Checketts D; VanLandingham KE; Zuberi SM;
    N Engl J Med; 2018 May; 378(20):1888-1897. PubMed ID: 29768152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
    Porcari GS; Fu C; Doll ED; Carter EG; Carson RP
    Epilepsy Behav; 2018 Mar; 80():240-246. PubMed ID: 29429908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience.
    Chen KA; Farrar M; Cardamone M; Gill D; Smith R; Cowell CT; Truong L; Lawson JA
    Med J Aust; 2018 Aug; 209(5):217-221. PubMed ID: 30092753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures.
    Klein P; Tolbert D; Gidal BE
    Epilepsy Behav; 2019 Oct; 99():106459. PubMed ID: 31519475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol.
    Szaflarski JP; Hernando K; Bebin EM; Gaston TE; Grayson LE; Ampah SB; Moreadith R
    Epilepsy Behav; 2019 Jun; 95():131-136. PubMed ID: 31048098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
    Devinsky O; Patel AD; Thiele EA; Wong MH; Appleton R; Harden CL; Greenwood S; Morrison G; Sommerville K;
    Neurology; 2018 Apr; 90(14):e1204-e1211. PubMed ID: 29540584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cannabidiol in children with refractory epileptic encephalopathy.
    Cáceres Guido P; Riva N; Caraballo R; Reyes G; Huaman M; Gutierrez R; Agostini S; Fabiana Delaven S; Pérez Montilla CA; García Bournissen F; Schaiquevich P
    Epilepsia; 2021 Jan; 62(1):e7-e12. PubMed ID: 33280111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects.
    Morrison G; Crockett J; Blakey G; Sommerville K
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1009-1031. PubMed ID: 30791225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial.
    Scheffer IE; Hulihan J; Messenheimer J; Ali S; Keenan N; Griesser J; Gutterman DL; Sebree T; Sadleir LG
    JAMA Netw Open; 2021 Sep; 4(9):e2123930. PubMed ID: 34477852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.